Technology

With Pafendyo and Kisunra Set to Join the Market Next Year… Which Domestic Companies Will Benefit from Eli Lilly Korea’s Growth?

NA EUN-KYUNG
2026-11-22 08:01:03
[Edaily Reporter NA EUN-KYUNG ] #Eli Lilly Korea is increasingly likely to rank first in sales among multinational pharmaceutical companies in Korea this year, driven by expanded sales of its obesity treatment “Mounjaro.” Following a nearly threefold increase in sales last year, the company is expected to surpass 1 trillion won in annual revenue for the first time this year. Next year, the oral obesity treatment “Foundeo” and the Alzheimer’s disease treatment “Kysunra” are expected to join the lineup. As Lilly Korea is expected to continue its growth momentum with a series of new product launches, domestic pharmaceutical distributors and diagnostic companies are also keeping a close eye on Lilly’s business expansion.

On the 17th, a representative from Eli Lilly Korea stated, “We expect ‘Foundeo’ to be launched in Korea sometime next year.” Unlike “Mounjaro,” an existing injectable obesity treatment, “Foundeo” is an oral obesity treatment. With “Kysunra” also currently undergoing the domestic approval process, these two new products are expected to serve as additional growth drivers for Eli Lilly Korea next year, further solidifying its position as the market leader.

Eli Lilly’s oral GLP-1 obesity treatment “Foundeo” (left) and Alzheimer’s disease antibody treatment “Kysunla” (right) (Photo: Eli Lilly)

Mounjaro Triples Sales… Will It Set New Records Next Year Too?
Lilly Korea’s
sales
this year are highly likely to exceed 1 trillion won for the first time. According to pharmaceutical market research firm IQVIA, the domestic distribution value of the obesity treatment “Mounjaro” reached approximately 744.4 billion won in the first half of this year. This figure has already far surpassed Lilly Korea’s total revenue of 482.1 billion won for all of last year—achieved in just six months with a single product. Although IQVIA’s distribution figures and the corporate revenue reported in audit reports are based on different accounting standards, observers note that given Mounjaro’s sales trend, there is a high probability that Lilly Korea will rank first in revenue among multinational pharmaceutical companies in Korea this year.

Lilly Korea’s rapid growth gained momentum following the launch of its obesity treatment. Lilly Korea’s revenue last year was 482.1 billion won, a 193.6% increase from 164.2 billion won in 2024. Once again, Mounjaro—launched in August of last year—drove the surge in performance.

During the same period, sales at Novartis Korea—the top-ranked multinational pharmaceutical company in the domestic market—reached 721.3 billion won, a 6.3% increase from the previous year. Novo Nordisk Korea grew by 85.6% thanks to expanded sales of the obesity treatment “Wegovy.” In contrast, Pfizer Korea and MSD Korea saw negative growth of 25.2% and 14.2%, respectively. Amid mixed performance among major multinational pharmaceutical companies, Lilly Korea stood out with a growth rate of 193.6%.

Growth is also expected next year through the launch of new products. Fundeyo is an oral obesity treatment that received approval in China this year following its approval in the U.S.; in Korea, the company has applied for marketing authorization with the Ministry of Food and Drug Safety and is awaiting the review results. If the launch materializes next year, Lilly Korea will expand its obesity treatment portfolio by adding the oral medication to its existing injectable product, Mounjaro.

Kysunra is also generating high expectations as a new revenue source. Kysunra is an antibody therapy for Alzheimer’s disease that targets beta-amyloid accumulated in the brain. Lilly Korea applied for domestic marketing authorization last November, and it is reported that the review is now in its final stages. Once commercialized in Korea, revenue from the Alzheimer’s disease treatment is expected to complement the company’s existing growth driven by obesity treatments.
From Pharmaceutical Distribution to Dementia Diagnostics… Which Domestic Companies Will Benefit
? First, domestic companies involved in the distribution of Mounjaro are expected to benefit directly from Lilly Korea’s increased sales. BLUEMTEC CO., LTD.(439580)is one of the domestic distributors selected by Lilly Korea for Mounjaro. In tandem with the expansion of Mounjaro sales, BLUEMTEC CO., LTD.’s consolidated revenue for the third quarter of this year reached 90.4 billion won, a 73.4% increase compared to the same period last year.

Affiliates of the GC Biopharma Corp. are also drawing attention. GCGREEN CROSS WellBeing Corporation(234690)began marketing the product to hospitals and clinics upon Mounjaro’s launch. GC Biopharma Corp. affiliate UBCARE CO., LTD.(032620)(formerly U-Care) is also supplying Mounjaro through its pharmaceutical distribution platform, “MisoMall.com.” Although the domestic distributor for Pandeyo has not yet been finalized, if Lilly Korea utilizes its existing distribution network, these companies are also expected to see opportunities for additional revenue growth.

Alzheimer’s disease diagnostic companies are also expected to benefit from the launch of Kisunla. This is because administering anti-amyloid antibody therapies such as Kisunla and Lecembi requires confirming the presence of beta-amyloid pathology in the patient’s brain. Positron emission tomography (PET) scans are one of the primary methods used to confirm this.

DuChemBio Co.,LTD.(176750), which effectively holds a monopoly on the domestic amyloid PET diagnostic market, is considered the biggest beneficiary. DuChemBio Co, LTD is responsible for domestic production after licensing the technologies for “Vizamil” and “NeuraCheck,” developed by GE Healthcare and Germany’s Life Molecular Imaging (LMI), respectively. It sells “Vizamil” directly and supplies “NeuraCheck” to Kai Biotech—which holds the domestic sales rights—through a contract manufacturing arrangement. According to DuChemBio Co, LTD, the combined production value of “Vizamil” and “NeuraCheck” last year was 11.81 billion won, accounting for 96.3% of the total production value of radiopharmaceuticals for Alzheimer’s disease diagnosis in South Korea. In the first three quarters of this year, combined sales of Vizamil and Neuracheck reached 7.1 billion won, a 32.7% increase compared to the same period last year. Diagnostic demand, which began to rise following the domestic launch of “Lecembi” in November 2024, is expected to expand further with the launch of Kisunla.

In particular, Kisunra has the potential to generate additional demand for PET scans compared to the existing Lecembi. According to U.S. approval guidelines, treatment with Kisunra can be discontinued once beta-amyloid plaques in the brain have decreased to a minimum level as determined by an amyloid PET scan. This means that PET scans must be used not only to screen patients before treatment but also to determine whether to continue treatment during the course of therapy; if the same criteria are applied in Korea, the increase in demand for PET diagnostic agents resulting from expanded Kisunra prescriptions is expected to be even greater.

DuChemBio Co, LTD also appears to be preparing for this increase in demand. A company official explained, “We have invested in the manufacturing facility at Hanyang University Hospital to meet the growing domestic demand for radiopharmaceutical diagnostic products, including amyloid PET diagnostic agents,” adding, “We are working to ensure patients can receive treatment without delays.”

FutureChem Co., Ltd.(220100)FutureChem Co., Ltd. is another company worth watching. FutureChem Co., Ltd. has a track record of signing contract manufacturing (CMO) agreements with Avid, a subsidiary of Eli Lilly, for the Alzheimer’s disease PET diagnostic agents “Amivid” and “Tauvid.” The initial contract was signed in 2022 and extended in 2024, remaining in effect until the end of 2027. Since this is a clinical contract rather than a commercial one, the contract value is only 3.13 billion won; however, the market is watching to see whether the existing clinical contract will be expanded to commercial production following the commercial launch of Kisunra.

However, FutureChem Co., Ltd. has taken a cautious stance regarding the potential expansion of the commercial contract. A FutureChem Co., Ltd. official told PharmDaily, “We believe there is potential for business opportunities to expand in line with future growth in the Alzheimer’s diagnosis market,” but added, “It is difficult to comment at this stage on whether individual contracts will be expanded or on specific business plans.”

While Neuracheck and Vizamil, produced by DuChemBio Co, LTD, and Amibid, produced by FutureChem Co., Ltd., are all diagnostic agents that target beta-amyloid, Tauvid visualizes tau protein pathology associated with Alzheimer’s disease. Although the first three products compete in the same diagnostic market, Tauvid stands out as a complementary test that provides different pathological information.

#NEUROPHET Inc., an AI company specializing in brain image analysis, is also expected to benefit indirectly. NEUROPHET Inc. provides software that supports patient screening prior to the administration of Alzheimer’s disease antibody therapies and the monitoring of amyloid-related imaging adverse reactions (ARIA) that may occur during treatment. Although “NEUROPHET Inc. AQUA AD Plus” is not the standard diagnostic method for Kysena, the company explains that it supports quantitative analysis of magnetic resonance imaging (MRI) and PET scans, as well as imaging analysis of amyloid-related imaging abnormalities (ARIA), thereby assisting healthcare professionals with imaging evaluations during anti-amyloid therapy.

A NEUROPHET Inc. representative stated, “As the related diagnostic and monitoring systems expand alongside the launch of Kyseonra, opportunities to utilize the NEUROPHET AQUA AD Plus imaging analysis solution will also grow,” adding “We are strengthening the competitiveness of our imaging analysis technologies and products in line with the growing trend toward the use of anti-amyloid therapies, and following the domestic launch, we plan to continuously monitor demand from clinical settings and the needs of healthcare professionals to ensure the solution is put to practical use.”

Economy

Corporation

IT·Science

Economy

Securities Tokenization: How Will Settlement Change?

If you sell stocks on Monday, the sale will appear immediately in your brokerage account. Assuming there are no market holidays in between, you can transfer the proceeds from the sale to your bank acc…
2026-11-22 05:00:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

With Pafendyo and Kisunra Set to Join the Market Next Year… Which Domestic Companies Will Benefit from Eli Lilly Korea’s Growth?

#Eli Lilly Korea is increasingly likely to rank first in sales among multinational pharmaceutical companies in Korea this year, driven by expanded sales of its obesity treatment “Mounjaro.” Following …
2026-11-22 08:01:03